TRCT
DGX icon

Tower Research Capital (TRC)’s Quest Diagnostics DGX Stock Holding History

Tower Research Capital (TRC)’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$407K Sell
2,077
-2,766
-57% -$537K 0.01% 1067
2025
Q4 		$840K Sell
4,843
-171
-3% -$31.1K 0.02% 573
2025
Q3 		$956K Buy
5,014
+1,987
+66% +$353K 0.03% 529
2025
Q2 		$544K Sell
3,027
-2,399
-44% -$417K 0.01% 911
2025
Q1 		$918K Buy
5,426
+6
+0.1% +$986 0.03% 538
2024
Q4 		$818K Sell
5,420
-1,134
-17% -$176K 0.02% 735
2024
Q3 		$1.02M Buy
6,554
+668
+11% +$99.8K 0.03% 523
2024
Q2 		$806K Buy
5,886
+2,639
+81% +$361K 0.01% 935
2024
Q1 		$432K Sell
3,247
-11,576
-78% -$1.5M 0.01% 947
2023
Q4 		$2.04M Buy
14,823
+9,706
+190% +$1.28M 0.03% 503
2023
Q3 		$624K Sell
5,117
-21,113
-80% -$2.81M 0.02% 752
2023
Q2 		$3.69M Buy
26,230
+24,571
+1,481% +$3.39M 0.12% 112
2023
Q1 		$235K Sell
1,659
-879
-35% -$126K 0.01% 1275
2022
Q4 		$397K Sell
2,538
-4,834
-66% -$695K 0.02% 834
2022
Q3 		$904K Sell
7,372
-3,545
-32% -$467K 0.01% 751
2022
Q2 		$1.45M Sell
10,917
-16,834
-61% -$2.29M 0.03% 486
2022
Q1 		$3.8M Buy
27,751
+17,383
+168% +$2.42M 0.04% 379
2021
Q4 		$1.79M Buy
10,368
+8,538
+467% +$1.3M 0.03% 455
2021
Q3 		$265K Sell
1,830
-2,986
-62% -$437K 0.01% 1538
2021
Q2 		$635K Sell
4,816
-4,556
-49% -$597K 0.02% 981
2021
Q1 		$1.2M Buy
9,372
+585
+7% +$72.1K 0.02% 673
2020
Q4 		$1.05M Buy
8,787
+3,792
+76% +$462K 0.03% 498
2020
Q3 		$571K Buy
4,995
+752
+18% +$88.8K 0.01% 1542
2020
Q2 		$483K Buy
+4,243
New +$450K 0.02% 1065
2020
Q1 		– Sell
-30
Closed -$3K – 3201
2019
Q4 		$3K Sell
30
-2,983
-99% -$311K ﹤0.01% 2889
2019
Q3 		$322K Buy
3,013
+2,521
+512% +$259K 0.02% 778
2019
Q2 		$50K Sell
492
-4,561
-90% -$438K ﹤0.01% 1570
2019
Q1 		$454K Buy
5,053
+2,913
+136% +$252K 0.03% 658
2018
Q4 		$178K Buy
2,140
+1,948
+1,015% +$183K 0.01% 724
2018
Q3 		$21K Sell
192
-4,420
-96% -$485K ﹤0.01% 2310
2018
Q2 		$507K Buy
+4,612
New +$480K 0.03% 640
2018
Q1 		– Sell
-349
Closed -$35K – 3363
2017
Q4 		$35K Sell
349
-136
-28% -$12.9K ﹤0.01% 1606
2017
Q3 		$45K Buy
+485
New +$51.5K ﹤0.01% 2057
2017
Q1 		– Sell
-2,783
Closed -$256K – 3209
2016
Q4 		$256K Buy
+2,783
New +$240K 0.03% 544
2016
Q3 		– Sell
-732
Closed -$60K – 3776
2016
Q2 		$60K Buy
732
+429
+142% +$32.7K 0.01% 1432
2016
Q1 		$22K Buy
+303
New +$20.3K ﹤0.01% 1268
2015
Q3 		– Sell
-306
Closed -$22K – 4137
2015
Q2 		$22K Sell
306
-1,060
-78% -$78.3K ﹤0.01% 2012
2015
Q1 		$105K Buy
+1,366
New +$97.8K 0.01% 844
2014
Q4 		– Sell
-7,459
Closed -$453K – 4124
2014
Q3 		$453K Buy
+7,459
New +$460K 0.05% 278
2014
Q2 		– Sell
-218
Closed -$13K – 4122
2014
Q1 		$13K Sell
218
-3,464
-94% -$186K ﹤0.01% 2332
2013
Q4 		$197K Buy
3,682
+253
+7% +$15K 0.03% 524
2013
Q3 		$212K Buy
3,429
+3,112
+982% +$186K 0.02% 713
2013
Q2 		$19K Buy
+317
New +$18.9K ﹤0.01% 1757

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Tower Research Capital (TRC)'s DGX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Quest Diagnostics (DGX) stake by 57% in Q1 2026, selling an estimated $537K and leaving 2,077 shares worth $407K. The position accounts for 0.01% of the portfolio, ranked #1067.

Tower Research Capital (TRC) first reported a position in DGX in Q2 2013 and has held it in 43 quarters since. The position peaked at $3.8M in Q1 2022. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Tower Research Capital (TRC) held 2,077 shares of Quest Diagnostics worth $407K as of Q1 2026.
  • Tower Research Capital (TRC) sold 2,766 Quest Diagnostics shares in Q1 2026, an estimated $537K.
  • Quest Diagnostics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1067 holding.
  • Tower Research Capital (TRC) first reported a position in Quest Diagnostics in Q2 2013 and has held it in 43 quarters since.
  • Tower Research Capital (TRC)'s Quest Diagnostics position peaked at $3.8M in Q1 2022.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.